New insights from long-term clinical use of ctDNA-based minimal residual disease monitoring in translocation-associated sarcomas
{{output}}
Introduction: Assessment of circulating tumor DNA (ctDNA) as means to monitor disease activity in translocation-associated tumors has become very popular in clinical practice. However, there are still few studies on its clinical ... ...
